# Minetta C. Liu

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/minetta-c-liu/

## Facts

| Field | Value |
| --- | --- |
| Citations | 19,140 |
| Field | Cancer Genomics and Diagnostics |
| h-index | 62 |
| i10-index | 165 |
| Last Known Institution | Natera (United States) |
| OpenAlex ID | https://openalex.org/A5027858713 |
| ORCID iD | https://orcid.org/0000-0002-8206-5232 |
| Works | 602 |

## Researcher papers

- [Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA](https://scholariq.org/papers/sensitive-and-specific-multi-cancer-detection-and-localization-using-methylation/)
- [Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer](https://scholariq.org/papers/effect-of-pembrolizumab-plus-neoadjuvant-chemotherapy-on-pathologic-complete/)
- [Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer](https://scholariq.org/papers/adaptive-randomization-of-veliparib-carboplatin-treatment-in-breast-cancer/)
- [Adaptive Randomization of Neratinib in Early Breast Cancer](https://scholariq.org/papers/adaptive-randomization-of-neratinib-in-early-breast-cancer/)
- [w4200350191](https://scholariq.org/papers/w4200350191/)
- [Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial](https://scholariq.org/papers/durvalumab-with-olaparib-and-paclitaxel-for-high-risk-her2-negative-stage-ii-iii/)
- [Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update—Integration of Results From TAILORx](https://scholariq.org/papers/use-of-biomarkers-to-guide-decisions-on-adjuvant-systemic-therapy-for-women-with/)
- [Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer](https://scholariq.org/papers/association-of-event-free-and-distant-recurrence-free-survival-with-individual/)
- [ctDNA-based molecular residual disease and survival in resectable colorectal cancer](https://scholariq.org/papers/ctdna-based-molecular-residual-disease-and-survival-in-resectable-colorectal/)
- [Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2.](https://scholariq.org/papers/pembrolizumab-plus-standard-neoadjuvant-therapy-for-high-risk-breast-cancer-bc/)

## Researcher topics

- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Cancer Cells and Metastasis](https://scholariq.org/topics/cancer-cells-and-metastasis/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [Natera (United States)](https://scholariq.org/institutions/natera-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.